Bio-Techne has bought University of Minnesota-founded genome editing platform operator B-Mogen Biotechnologies to solidify a business relationship that dates to 2016.
B-Mogen Biotechnologies, a US-based genome editing services spinout of University of Minnesota, has been purchased by biotech and clinical diagnostics products supplier Bio-Techne for an undisclosed sum, StarTribune reported yesterday.
While terms were not disclosed, Bio-Techne confirmed it would directly fund the acquisition from its cash holdings.
Founded in 2015, B-Mogen Biotechnologies provides strategic support and other services for genomic engineering with the purpose of making drug development programs including gene and cell therapies more effective.
Services offered by B-Mogen Biotechnologies fall into three subdivisions – therapeutic genome engineering, mitochondrial genome engineering and applications with broad appeal such as cell line services and pluripotent stem cell engineering.
The company’s founding intellectual property was created by three researchers from the paediatrics department at University of Minnesota’s medical school – assistant professors Branden Moriarity and Beau Webber, and Prof David Largaespada.
Bio-Techne believes the acquisition will strengthen…
